HUP0201222A3 - Use of soluble constimulatory molecules to enhance immune responses - Google Patents

Use of soluble constimulatory molecules to enhance immune responses

Info

Publication number
HUP0201222A3
HUP0201222A3 HU0201222A HUP0201222A HUP0201222A3 HU P0201222 A3 HUP0201222 A3 HU P0201222A3 HU 0201222 A HU0201222 A HU 0201222A HU P0201222 A HUP0201222 A HU P0201222A HU P0201222 A3 HUP0201222 A3 HU P0201222A3
Authority
HU
Hungary
Prior art keywords
soluble
immune responses
enhance immune
constimulatory molecules
constimulatory
Prior art date
Application number
HU0201222A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Genetics Inst Llc Delaware All
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Inst Llc Delaware All filed Critical Genetics Inst Llc Delaware All
Publication of HUP0201222A2 publication Critical patent/HUP0201222A2/hu
Publication of HUP0201222A3 publication Critical patent/HUP0201222A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
HU0201222A 1999-05-06 2000-05-05 Use of soluble constimulatory molecules to enhance immune responses HUP0201222A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13294499P 1999-05-06 1999-05-06

Publications (2)

Publication Number Publication Date
HUP0201222A2 HUP0201222A2 (en) 2002-08-28
HUP0201222A3 true HUP0201222A3 (en) 2004-07-28

Family

ID=22456295

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0201222A HUP0201222A3 (en) 1999-05-06 2000-05-05 Use of soluble constimulatory molecules to enhance immune responses

Country Status (15)

Country Link
EP (1) EP1181053A2 (fr)
JP (1) JP2002544170A (fr)
KR (1) KR20020001865A (fr)
CN (1) CN1377279A (fr)
AU (1) AU4825700A (fr)
BR (1) BR0010711A (fr)
CA (1) CA2373256A1 (fr)
CZ (1) CZ20013964A3 (fr)
HK (1) HK1041810A1 (fr)
HU (1) HUP0201222A3 (fr)
IL (1) IL146106A0 (fr)
NO (1) NO20015396L (fr)
PL (1) PL360915A1 (fr)
WO (1) WO2000067788A2 (fr)
ZA (1) ZA200109376B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
EP3138844B1 (fr) * 2005-06-30 2018-05-02 Eisai R&D Management Co., Ltd. Composés pour préparer un adjuvant immunologique
US7745215B2 (en) 2005-12-08 2010-06-29 University Of Louisville Research Foundation, Inc. Methods and compositions for expanding T regulatory cells
CA2632682A1 (fr) 2005-12-08 2007-06-14 University Of Louisville Research Foundation, Inc. Modification in vivo de surfaces cellulaires
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
JP2014521687A (ja) 2011-07-29 2014-08-28 セレクタ バイオサイエンシーズ インコーポレーテッド 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
JP2015513915A (ja) * 2012-04-02 2015-05-18 アリゾナ・ボード・オブ・リージェンツ・フォー・アンド・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティＡｒｉｚｏｎａ Ｂｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ Ｆｏｒ Ａｎｄ Ｏｎ Ｂｅｈａｌｆ Ｏｆ Ａｒｉｚｏｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ 細胞性免疫応答の誘導のための組換え細菌
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
TR201908418T4 (tr) 2013-11-04 2019-07-22 Uti Lp Sürdürülebilir immünoterapi için yöntem ve kompozisyonlar.
JP6920211B2 (ja) 2015-05-06 2021-08-18 ユーティーアイ リミテッド パートナーシップ 持続療法用のナノ粒子組成物
CN110743006B (zh) * 2019-11-22 2020-08-25 北京启辰生生物科技有限公司 用于协同解除免疫细胞衰竭的组合物及应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE251181T1 (de) * 1998-07-28 2003-10-15 Micromet Ag Heterominikörper

Also Published As

Publication number Publication date
NO20015396L (no) 2002-01-02
CZ20013964A3 (cs) 2002-06-12
BR0010711A (pt) 2002-02-13
PL360915A1 (en) 2004-09-20
JP2002544170A (ja) 2002-12-24
AU4825700A (en) 2000-11-21
CN1377279A (zh) 2002-10-30
KR20020001865A (ko) 2002-01-09
EP1181053A2 (fr) 2002-02-27
WO2000067788A3 (fr) 2001-04-05
HK1041810A1 (zh) 2002-07-26
IL146106A0 (en) 2002-07-25
HUP0201222A2 (en) 2002-08-28
WO2000067788A2 (fr) 2000-11-16
CA2373256A1 (fr) 2000-11-16
NO20015396D0 (no) 2001-11-05
ZA200109376B (en) 2003-03-13

Similar Documents

Publication Publication Date Title
HUP0201222A3 (en) Use of soluble constimulatory molecules to enhance immune responses
HK1061403A1 (en) ANTIBODIES TO HUMAN IL-1ß
IL144578A0 (en) Antibodies specific to kdr and uses thereof
HUP0200898A3 (en) Derivatives of venlafaxine and methods of preparing and using the same
AU1449401A (en) Method using prior activities to improve the completion of transaction
HUP0302352A3 (en) Sn-38 lipid complexes and methods of use
AU2002228890A1 (en) Use of zwitterionic polysaccharides for the specific modulation of immune processes
EP1293204A4 (fr) Preparation d'un gel a base d'uree
IL149614A0 (en) Novel use of antibodies as vaccines
EP1242071A4 (fr) Utilisation du parthenolide pour inhiber le cancer
HUP0201642A3 (en) Preparation of substituted piperidin-4-ones
HK1044817A1 (en) Use of 13c-nmr to detect binding
ID25939A (id) Peralatan untuk memproduksi makanan kecil
GB0130573D0 (en) Improvements to leg supports
IL157614A0 (en) Uses of opg ligand to modulate immune responses
EP1366056A4 (fr) Preparation de desoxynucleosides
PL355845A1 (en) Substituted isoquinoline derivatives and their use as inticonvulsants
AU5878600A (en) Novel chitosan-containing liquid compositions and methods for their preparation and use
PL346796A1 (en) Methods of downmodulating the immune response to therapeutic proteins
AU5801398A (en) The use of cd4-binding small molecules to inhibit immune responses
AU6019599A (en) Use of mcrp to enhance immune responses
AUPP942099A0 (en) Improvements to cooking apparatus
GB9929873D0 (en) Improvements in or relating to the reception of spread spectrum signals
AU4332900A (en) Use of interleukin-11 to treat gastrointestinal disorders
AU6074000A (en) Human immune response molecules